Coronavirus (SARS-CoV-2): a systematic review for potential vaccines

References

• Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, Haagmans BL, Lauber C, Leontovich AM, Neuman BW, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536–18.
   PubMed Web of Science ®Google Scholar
• Fauci AS, Lane HC, Redfield RR. Covid-19 - navigating the uncharted. N Engl J Med. 2020;382(13):1268–69. doi:10.1056/NEJMe2002387.
   PubMed Web of Science ®Google Scholar
• Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–74. doi:10.1016/S0140-6736(20)30251-8.
   PubMed Web of Science ®Google Scholar
• Chakraborty D, Debnath F, Biswas S, Bhatta M, Ganguly S, Deb AK, Saha MK, Dutta S. Exploring repurposing potential of existing drugs in the management of COVID-19 epidemic: a critical review. J Clin Med Res. 2020;12(8):463–71. doi:10.14740/jocmr4241.
   PubMedGoogle Scholar
• Cavanagh D. Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus. Avian Pathol. 2003;32(6):567–82. doi:10.1080/03079450310001621198.
   PubMed Web of Science ®Google Scholar
• Ruggieri A, Di Trani L, Gatto I, Franco M, Vignolo E, Bedini B, Elia G, Buonavoglia C. Canine coronavirus induces apoptosis in cultured cells. Vet Microbiol. 2007;121(1–2):64–72A. doi:10.1016/j.vetmic.2006.12.016.
   PubMed Web of Science ®Google Scholar
• Paltrinieri S, Metzger C, Battilani M, Pocacqua V, Gelain M, Giordano A. Serum α1-acid glycoprotein (AGP) concentration in non-symptomatic cats with feline coronavirus (FCoV) infection. J Feline Med Surg. 2007;9(4):271–7A. doi:10.1016/j.jfms.2007.01.002.
   PubMed Web of Science ®Google Scholar
• Tripp RA, Haynes LM, Moore D, Anderson B, Tamin A, Harcourt BH, Jones LP, Yilla M, Babcock GJ, Greenough T, et al. Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins. J Virol Methods. 2005;128(1–2):21–28. doi:10.1016/j.jviromet.2005.03.021.
   PubMed Web of Science ®Google Scholar
• Shehata MM, Gomaa MR, Ali MA, Kayali G. Middle East respiratory syndrome coronavirus: a comprehensive review. Front Med. 2016;10(2):120–36. doi:10.1007/s11684-016-0430-6.
   PubMed Web of Science ®Google Scholar
• Jiang S, Lu L, Du L. Development of SARS vaccines and therapeutics is still needed. Future Virol. 2013;8(1):1–2. doi:10.2217/fvl.12.126.
   PubMed Web of Science ®Google Scholar
• Yong CY, Ong HK, Yeap SK, Ho KL, Tan WS. Recent advances in the vaccine development against middle east respiratory syndrome-coronavirus. Front Microbiol. 2019;10:1781. doi:10.3389/fmicb.2019.01781.
   PubMed Web of Science ®Google Scholar
• Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, Reuschel EL, Robb ML, Racine T, Oh M-D, et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. The Lancet Infectious Diseases. 2019;19(9):1013–22.
   PubMed Web of Science ®Google Scholar
• Butler D. SARS veterans tackle coronavirus. Nature. 2012;490(7418):20. Bibcode: 2012 Nature 490-20B. doi:10.1038/490020a.
   PubMed Web of Science ®Google Scholar
• Estola T. Coronaviruses, a new group of animal RNA viruses. Avian Dis. 1970;14(2):330–36. doi:10.2307/1588476.
   PubMed Web of Science ®Google Scholar
• Almeida JD, Berry DM, Cunningham CH, Hamre D, Hofstad MS, Mallucci L, McIntosh K, Tyrrell DAJ. Virology: coronaviruses. Nature. 1968;220:650.
   Google Scholar
• Tyrrell DA, Fielder M. Cold Wars: the fight against the common cold. Oxford: Oxford University Press; 2002. p. 96. ISBN 0 19 263285 X
   Google Scholar
• Payne S. ed. Chapter 17 - family coronaviridae, viruses. USA: Academic Press; 2017. p. 149–58.
   Google Scholar
• Su S, Wong G, Shi W, Liu J, Lai AC, Zhou J, Liu W, Bi Y, Gao GF. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24(6):490–502. doi:10.1016/j.tim.2016.03.003.
   PubMed Web of Science ®Google Scholar
• Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1–23. doi:10.1007/978-1-4939-2438-7_1
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–69. doi:10.7326/0003-4819-151-4-200908180-00135.
   PubMed Web of Science ®Google Scholar
• McGrail S. Sanofi, GSK partner to develop adjuvanted COVID-19 vaccine. In: Murphy KS. Denvers: Pharma News Intelligence, Xtelligent Healthcare Media; 2020.
   Google Scholar
• Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, Haagmans BL, Lauber C, Leontovich AM, Neuman BW, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536–54.
   PubMed Web of Science ®Google Scholar
• World Health Organization timeline - COVID-19. World health organization. 27 April 2020
   Google Scholar
• Kim E, Okada K, Kenniston T, Raj VS, AlHajri MM, Farag EA, AlHajri F, Osterhaus ADME, Haagmans BL, Gambotto A, et al. Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice. Vaccine. 2014;32(45):5975–82. doi:10.1016/j.vaccine.2014.08.058.
   PubMed Web of Science ®Google Scholar
• Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas WD, Coccia JA, Graziano R, Srinivasan M, Lowy I, Finberg R, et al. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis. 2005;191(4):507–14A. doi:10.1086/427242.
   PubMed Web of Science ®Google Scholar
• Roberts A, Thomas WD, Guarner J, Lamirande EW, Babcock GJ, Greenough TC, Vogel L, Hayes N, Sullivan J, Zaki S, et al. Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters. J Infect Dis. 2006;193(5):685–92. doi:10.1086/500143.
   PubMed Web of Science ®Google Scholar
• Gao W, Tamin A, Soloff A, D’Aiuto L, Nwanegbo E, Robbins PD, Bellini WJ, Barratt-Boyes S, Gambotto A. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet. 2003;362(9399):1895–96. doi:10.1016/S0140-6736(03)14962-8.
   PubMed Web of Science ®Google Scholar
• Boodman E. Researchers rush to test coronavirus vaccine inpeople without knowing how well it works in animals. Boston: STAT. 2020. p. 1.
   PubMed Web of Science ®Google Scholar
• Graham BS. Rapid COVID-19 vaccine development. Science. 2020;368(6494):945–46. doi:10.1126/science.abb8923.
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Corry DB, Bottazzi ME. COVID-19 vaccine design: the Janus face of immune enhancement. Nat Rev Immunol. 2020;20:347–48. doi:10.1038/s41577-020-0323-4.
   PubMed Web of Science ®Google Scholar
• Vardhana SA, Wolchok JD. The many faces of the anti-COVID immune response. J Exp Med. 2020;217:e20200678. doi:10.1084/jem.20200678.
   PubMed Web of Science ®Google Scholar
• Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, Baxter-Stoltzfus A, Laurence J. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;5:S1931–S5244.
   Google Scholar
• Funk CD, Laferrière C, Ardakani A. A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic. Front Pharmacol. 2020;11:937. doi:10.3389/fphar.2020.00937.
   PubMed Web of Science ®Google Scholar
• Cortis D. On determining the age distribution of COVID-19 pandemic. Front Public Health. 2020;8:202. doi:10.3389/fpubh.2020.00202.
   PubMed Web of Science ®Google Scholar
• Bhatta M, Nandi S, Dutta N, Dutta S, Saha MK. HIV care among elderly population: systematic review and meta-analysis. AIDS Res Hum Retroviruses. 2020;36(6):475–89. doi:10.1089/aid.2019.0098.
   PubMed Web of Science ®Google Scholar
• Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, Mayhew S. The COVID-19 vaccine development landscape. Nature Reviews Drug Discovery. 2020;19:305–306. doi:10.1038/d41573-020-00073–5.
   Google Scholar
• Lee CE, Welker K, Perlmutter-Gumbiner E. Health officials eyeing at least one of 14 potential coronavirus vaccines to fast-track. NBC News. 2020.
   Google Scholar
• COVID-19 treatment and vaccine tracker (PDF). Milken Institute.
   Google Scholar
• Hegarty P, Kamat A, Zafirakis H, Dinardo A. BCG vaccination may be protective against Covid-19. Researchgate preprint. 2020. doi:10.13140/RG.2.2.35948.10880
   Google Scholar
• Kleinnijenhuis J, van Crevel R, Netea MG. Trained immunity: consequences for the heterologous effects of BCG vaccination. Trans R Soc Trop Med Hyg. 2015;109(1):29–35. doi:10.1093/trstmh/tru168.
   PubMed Web of Science ®Google Scholar
• de Vrieze J. Can a century-old TB vaccine steel the immune system against the new coronavirus? Science. 2020;370:8297. doi:10.1126/science.370.6519.895.
   Google Scholar
• Bacille Calmette-Guérin (BCG) vaccination and COVID-19. World health organization (WHO). April 2020.
   Google Scholar
• EudraCT 2020-000919-69. EU clinical trials register.
   Google Scholar
• Murdoch Children’s Research Institute to trial preventative vaccine for COVID-19 healthcare workers. Murdoch children’s research institute.
   Google Scholar
• BCG Vaccination to Protect Healthcare Workers Against COVID-19. ClinicalTrials.gov.
   Google Scholar
• BCG Vaccine for Health Care Workers as Defence Against SARS-COV2. ClinicalTrials.gov.
   Google Scholar
• Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19. ClinicalTrials.gov.
   Google Scholar
• EudraCT Number 2020-001591-15. EU Clinical Trials Register.
   Google Scholar
• Performance Evaluation of BCG vs COVID-19. ClinicalTrials.gov.
   Google Scholar
• COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement - Full Text View - ClinicalTrials.gov. US National Library of Medicine, National Institutes of Health. clinicaltrials.gov.
   Google Scholar
• EudraCT Number 2020-001678-31. EU clinical trials register. EU.
   Google Scholar
• Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic - Full Text View - ClinicalTrials.gov. US National Library of Medicine, National Institutes of Health. clinicaltrials.gov
   Google Scholar
• WHO. Bacille Calmette-Guérin (BCG) vaccination and COVID-19-Scientific Brief. 2020.
   Google Scholar
• https://www.who.int/news-room/commentaries/detail/bacille-calmette-gu%C3%A9rin-(bcg)-vaccination-and-covid-19
   Google Scholar
• Gupta T, Gupta SK. Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses. Int Immunopharmacol. 2020;86:106717. doi:10.1016/j.intimp.2020.106717.
   PubMed Web of Science ®Google Scholar
• Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, Nkolola JP, Liu J, Li Z, Chandrashekar A, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020;369:806–11. doi:10.1126/science.abc6284.
   PubMed Web of Science ®Google Scholar
• Liu A. China’s CanSino Bio advances COVID-19 vaccine into phase 2 on preliminary safety data. FiercePharma. 2020. Accessed 13 April 2020. “‘ CanSino and its collaborators at the Academy of Military Medical Sciences’ Institute of Biotechnology plan to move their adenovirus type-5 vector-based recombinant COVID-19 vaccine, Ad5-nCoV, into phase 2 clinical trial in China “soon”,’ the company said in a disclosure (PDF) to the Hong Kong Stock Exchange on Thursday. Archived from the original on 30 April 2020.
   Google Scholar
• Clinical trial number NCT04341389 for “A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) at ClinicalTrials.gov.
   Google Scholar
• Clinical trial number NCT04313127 for “A Phase I Clinical Trial in 18-60 Adults at clinicalTrials.gov.
   Google Scholar
• EudraCT Number 2020-001038-36. EU Clinical Trials Register. European Union.
   Google Scholar
• Clinical trial number NCT04324606 for A Study of a Candidate COVID-19 Vaccine (COV001) at ClinicalTrials.gov.
   Google Scholar
• Clinical trial number NCT04444674 for A Study of a Candidate COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African adults with and without HIV-infection at ClinicalTrials.gov.
   Google Scholar
• University of Oxford commences clinical trial for vaccine candidate (ChAdOx1 nCoV-19) Targeting COVID-19. Trial Site News. 31 March 2020.
   Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–78. doi:10.1016/S0140-6736(20)31604-4.
   PubMed Web of Science ®Google Scholar
• Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, Reuschel EL, Robb ML, Racine T, Oh MD, et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis. 2019;19(9):1013–22.
   PubMed Web of Science ®Google Scholar
• Clinical trial number NCT04336410 for Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers at ClinicalTrials.gov.
   Google Scholar
• IVI, INOVIO, and KNIH to partner with CEPI in a Phase I/II clinical trial of INOVIO’s COVID-19 DNA vaccine in South Korea. International Vaccine Institute. 16 April 2020.
   Google Scholar
• NIH clinical trial of investigational vaccine for COVID-19 begins. US national institutes of health. 16 March 2020.
   Google Scholar
• Clinical trial number NCT04283461 for Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection at ClinicalTrials.gov.
   Google Scholar
• Clinical trial number NCT04299724 for Safety and Immunity of Covid-19 aAPC Vaccine at ClinicalTrials.gov.
   Google Scholar
• Clinical trial number NCT04276896 for Immunity and Safety of Covid-19 Synthetic Minigene Vaccine at ClinicalTrials.gov.
   Google Scholar
• Clinical trial number NCT04334980 for Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19 at ClinicalTrials.gov. US National Library of Medicine, NIH.
   Google Scholar
• Clinical trial number NCT04352608 for Safety and Immunogenicity Study of 2019-nCoV Vaccine (Inactivated) for Prophylaxis SARS CoV-2 Infection (COVID-19) at ClinicalTrials.gov.
   Google Scholar
• A randomized, double-blind, placebo parallel-controlled phase I/II clinical trial for inactivated novel coronavirus pneumonia vaccine (Vero cells)”. Chinese Clinical Trial Registry. April 2020
   Google Scholar
• hyFc platform. [Accessed 2020 Apr 30]. http://www.genexine.com/m21.php
   Google Scholar
• Seo YB, Im SJ, Namkoong H, Kim SW, Choi YW, Kang MC, Lim HS, Jin HT, Yang SH, Cho ML, et al. Crucial roles of interleukin-7 in the development of T follicular helper cells and in the induction of humoral immunity. J Virol. 2014;88:8998–9009. doi:10.1128/JVI.00534-14.
   PubMed Web of Science ®Google Scholar
• Lee JH, Cho JH, Yeo J, Lee SH, Yang SH, Sung YC, Kang J-H, Park C-S. The pharmacology study of a new recombinant TNF receptor-hyFc fusion protein. Biologicals. 2013;41:77–83. doi:10.1016/j.biologicals.2012.09.001.
   PubMed Web of Science ®Google Scholar
• Loset GA, Roux KH, Zhu P, Michaelsen TE, Sandlie I. Differential segmental flexibility and reach dictate the antigen binding mode of chimeric IgD and IgM: implications for the function of the B cell receptor. J Immunol. 2004;172:2925–34. doi:10.4049/jimmunol.172.5.2925.
   PubMed Web of Science ®Google Scholar
• Kang MC, Park HW, Choi DH, Choi YW, Park Y, Sung YC, Lee S-W. Plasmacytoid dendritic cells contribute to the protective immunity induced by intranasal treatment with Fc-fused interleukin-7 against lethal influenza virus infection. Immune Netw. 2017;17:343–51. doi:10.4110/in.2017.17.5.343.
   PubMed Web of Science ®Google Scholar
• Tirado SM, Yoon KJ. Antibody-dependent enhancement of virus infection and disease. Viral Immunol. 2003;16:69–86. doi:10.1089/088282403763635465.
   PubMed Web of Science ®Google Scholar
• Khandia R, Munjal A, Dhama K, Karthik K, Tiwari R, Malik YS, Singh RK, Chaicumpa W. Modulation of dengue/zika virus pathogenicity by antibody-dependent enhancement and strategies to protect against enhancement in Zika Virus infection. Front Immunol. 2018;9:597. doi:10.3389/fimmu.2018.00597.
   PubMed Web of Science ®Google Scholar
• Wan Y, Shang J, Sun S, Tai W, Chen J, Geng Q, He L, Chen Y, Wu J, Shi Z, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J Virol. 2020;94(5):pii: e02015-19.92.
   Web of Science ®Google Scholar
• Wang SF, Tseng SP, Yen CH, Yang JY, Tsao CH, Shen CW, Chen K-H, Liu F-T, Liu W-T, Chen YMA, et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem Biophys Res Commun. 2014;451:208–14. doi:10.1016/j.bbrc.2014.07.090.
   PubMed Web of Science ®Google Scholar
• Duffy S. Why are RNA virus mutation rates so damn high? PLoS Biol. 2018;16:e3000003. doi:10.1371/journal.pbio.3000003.
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L, et al. A pneumonia outbreak as sociated with a new coronavirus of probable bat origin. Nature. 2020;579:270–73. doi:10.1038/s41586-020-2012-7.
   PubMed Web of Science ®Google Scholar
• Andre FE. The future of vaccines, immunization concepts and practice. Vaccine. 2001;19:2206–09. doi:10.1016/S0264-410X(00)00546-6.
   PubMed Web of Science ®Google Scholar
• CEPI. Our vaccine and platform portfolio. Coalition for Epidemic Preparedness Innovation (CEPI). 30 April 2020.
   Google Scholar
• CEPI collaborates with the Institute Pasteur in a consortium to develop COVID-19 vaccine. Coalition for Epidemic Preparedness Innovations. 19 March 2020
   Google Scholar
• Yeung J. Millions of chickens are used to make vaccines each year. But that won’t work for coronavirus. CNN. 2020.
   Google Scholar
• Di Masi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs”. J Health Econ. 2016;47:20–33. doi:10.1016/j.jhealeco.2016.01.012.
   PubMed Web of Science ®Google Scholar
• Lee BY, Brown ST, Korch GW, Cooley PC, Zimmerman RK, Wheaton WD, Zimmer SM, Grefenstette JJ, Bailey RR, Assi TM, et al. A computer simulation of vaccine prioritization, allocation, and rationing during the 2009 H1N1 influenza pandemic. Vaccine. 2010;28(31):4875–79. doi:10.1016/j.vaccine.2010.05.002.
   PubMed Web of Science ®Google Scholar
• Gouglas D, Le TT, Henderson K, Kaloudis A, Danielsen T, Hammersland NC, Robinson JM, Heaton PM, Røttingen JA. Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study. Lancet Global Health. 2018;6(12):e1386–e1396. doi:10.1016/S2214-109X(18)30346-2.
   PubMed Web of Science ®Google Scholar
• Strovel J, Sittampalam S, Coussens NP, Hughes M, Inglese J, Kurtz A, Andalibi A, Patton L, Austin C, Baltezor M, et al. Early drug discovery and development guidelines: for academic researchers, collaborators, and start-up companies. In: Markossian, Sittampalam S, editors. Assay guidance manual [Internet]. Eli Lilly & Company and the National Center for Advancing Translational Sciences. National Institute of Helth; 2020 (revised edition). p. 3–37.
   Google Scholar
• WHO. Public statement for collaboration on COVID-19 vaccine development. World Health Organization. 13 April 2020
   Google Scholar
• Jef A. COVID-19 vaccine frontrunners. The Scientist Magazine, April, 7, 2020.
   Google Scholar